Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenue
Total revenue	$ 1,020,177	$ 846,226
Operating expenses
Research and development	1,776,382	1,230,429
General and administrative	1,747,585	1,790,522
Sales and marketing	372,233	329,773
Impairment of right-of-use asset	520,759	0
Total operating expenses	4,782,143	3,862,109
Operating loss	(3,761,966)	(3,015,883)
Other (expense) income
Other (expense) income	(24,422)	5,298
Interest expense	(56,444)	(57,846)
Foreign currency transaction (losses) gains	(10,351)	12,181
Change in fair value of derivative financial instruments	67	8,166
Total other expense	(91,150)	(32,201)
Loss before income taxes	(3,853,116)	(3,048,084)
Provision for income taxes	0	0
Net loss	(3,853,116)	(3,048,084)
Net loss available to common stockholders	$ (3,853,116)	$ (3,048,084)
Net loss per common share - basic and diluted	$ (0.41)	$ (0.75)
Weighted average shares outstanding - basic and diluted	9,345,720	4,055,715
Net loss	$ (3,853,116)	$ (3,048,084)
Other comprehensive gain (loss) - foreign currency translations	2,826	(12,579)
Comprehensive loss	(3,850,290)	(3,060,663)
Product [Member]
Revenue
Total revenue	520,177	633,496
Operating expenses
Cost of products and services	220,702	342,832
Laboratory Service Revenue [Member]
Revenue
Total revenue	0	8,690
Collaborations Revenue [Member]
Revenue
Total revenue	500,000	204,040
Service [Member]
Operating expenses
Cost of products and services	$ 144,482	$ 168,553